A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Summary

The purpose of this study is to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in participants with advanced malignant solid tumors. Participants who do not complete both Cycle 1, Day 1, and Cycle 2, Day 1 according to schedule will be replaced for the purpose of analysis; these participants may continue to receive study therapy. No dose reductions, delayed or missed doses are allowed during Cycles 1 and 2.

Timeline

Start

2012-07

Primary completion

2012-12

Completion

2014-03

Drugs

Indications